Our business idea is to help people with chronic conditions and illnesses by using a patented treatment method that is neither surgical nor drug-based. The treatment is called Ozilia™ and is based on the Kinetic Oscillation Stimulation technology.
Ozilia™ is a product system for neurostimulation therapy with long-term effects, which modulates the autonomic nervous system functions. The rhinitis treatment is CE-certified and is sold in the EU. The migraine treatment is in a clinical trial phase, but was CE marked in May 2021 based on interim analysis data – and therefore currently under market introduction.
We want to establish our technology in the international market for neuromodulation. We sell our product system and our treatments through distributors to clinics and hospitals, who in turn treat the patients.
In November, 2022, the results of a clinical study were presented, showing that the effect of the Ozilia™ Migraine treatment is statistically significant, and scientifically proven to be an equivalent alternative to other migraine treatment methods on the market. The results support Chordate’s marketing activities.
Listed on Nasdaq First North Growth Market
Today, the company has three employees, supported by a handful of expert consultants with extensive overall experience in medical technology product development, international market establishment, and clinical study activities. The business is entirely focused on sales in a few selected markets and the implementation of the two ongoing studies.
Chordate Medical AB, the Group’s operating company, is a wholly owned subsidiary of Chordate Medical Holding AB (Publ), was listed on Nordic Growth Market-SME on March 8, 2017 and is since February 15, 2022, traded on Nasdaq First North Growth Market.
The company is based in Kista, outside Stockholm.